Agennix AG
http://www.agennix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agennix AG
Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
Agennix expires
At an extraordinary general meeting (EGM) on 22 May, Agennix shareholders voted in favor of the liquidation of the company. It will be dissolved by 31 May 2013, with liquidation slated to take at least a year following dissolution.
Agennix proposes liquidation
Agennix, which has looked doomed since the failure of its only significant asset last year, is considering two options ahead of an extraordinary general meeting (EGM) on 22 May 2013. It will ask shareholders to vote on two proposals: a 20:1 reverse stock split and liquidiation of the company.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- GPC Biotech AG